Squamous Cell Carcinoma of Head and Neck D000077195

Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Glandular and Epithelial » Carcinoma » Carcinoma, Squamous Cell » Squamous Cell Carcinoma of Head and Neck

Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Head and Neck Neoplasms » Squamous Cell Carcinoma of Head and Neck

Description

The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.   MeSH

Hierarchy View


Phase 2 Indicated Drugs (227)

Phase 1 Indicated Drugs (149)


Organization Involved with Phase 3 Indications (56)

Organization Involved with Phase 2 Indications (254)

Fujian Medical University

Genentech

Genmab

Genocea Biosciences, Inc.

Georgetown University

GKNM Hospital, Coimbatore, India

Glycotope GmbH

Gottfried Wilhelm Leibniz Universität Hannover

Government Medical College, Aurangabad, India

Government of Canada

Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Guizhou Medical University

Hannover Medical School

Harbin Medical University

Harvard University

Hellenic Cooperative Oncology Group

Henan Medical University

Hengrui Therapeutics, Inc.

HonorHealth Research Institute

Hoosier Cancer Research Network

Huazhong University of Science and Technology

Humboldt University

Icahn School of Medicine at Mount Sinai

Imclone

Immune Oncology Network

Immunicum AB

Immunomedics

Immunovative Therapies

Immutep S.A.

Indena S.p.A

Inovio Pharmaceuticals

Instituto do Cancer do Estado de São Paulo

Iovance

Ipsen

IQVIA

IRX Therapeutics

ISA Pharmaceuticals

IsoRay Medical, Inc.

Istituto Oncologico Veneto

Istituto Oncologico Veneto IRCCS

James and Esther King Biomedical Research Program

Jaslok Hospital and Research Centre, Mumbai, India

Jiangsu Cancer Institute & Hospital

Johns Hopkins University

Joseph Sanchez Foundation

J. W. Goethe University

Kadoorie Foundation

Karolinska Institute

Kura Oncology, Inc.

Kymab Limited

Leiden University

Lithuanian University of Health Sciences

Loyola University

Ludwig Institute for Cancer Research

Maastricht University

Mackay Medical College

Mayo Clinic

Medical Center Haaglanden

Medical Center Leeuwarden

Medical College of Wisconsin

Medical University of Vienna

MedImmune

Medisch Spectrum Twente

Meenakshi Ammal Dental College and Hospital

Memorial Hermann Health System

Merck Serono

Millennium Pharmaceuticals

Nanobiotix

NanoCarrier Co., Ltd.

NantCell, Inc.

National Baromedical Services

National Cancer Center, Korea

National Cancer Institute, France

National Comprehensive Cancer Network

National Institute of Dental and Craniofacial Research (NIDCR)

National Institutes of Health (NIH)

National Taiwan University

National University of Singapore

Nektar Therapeutics

Netherlands Cancer Institute

NextCure, Inc.

NKMAX Co., Ltd.

Novartis

Nova Scotia Health Authority

Ocellaris Pharma, Inc.

Ohio State University

Oncolys BioPharma Inc

OncoNano Medicine, Inc.

Onconova Therapeutics, Inc.

OncoSec Medical Incorporated

Oncovir, Inc.

OSI Pharmaceuticals

PCI Biotech AS

Peking University

Pennsylvania State University

People's Liberation Army of China

Peter MacCallum Cancer Centre

PharmaBio Development Inc.

Pharmaceutical Research Associates, Inc. (PRA)

Pharmacyclics

PharmaEngine

Phosplatin Therapeutics

PIQUR Therapeutics AG

Piramal

Plexxikon

PPD

Prisma Health

Providence Health & Services

Radboud University

Regeneron

Regional Cancer Centre, Trivandram

Royal Marsden Hospital NHS Trust

RTOG Foundation

Rutgers University

Samyang Biopharmaceuticals Corporation

Sanford Health

Seattle Genetics

Sensei Pharmaceuticals, Inc.

Seoul National University

Shanghai Henlius Biotech

Shanghai Junshi Bioscience Co.,Ltd.

Sichuan University

Southern Illinois University

Stanford University

State University of New York, Buffalo

Sungkyunkwan University

Symphogen A/S

SynCore Biotechnology

Takeda

TCRCure

Temple University

The Cleveland Clinic

Thomas Jefferson University

Threshold Pharmaceuticals

Tianjin Medical University

Transgene

Tsinghua University

TyrNovo Ltd.

UNICANCER

United States Air Force

Universidad Complutense de Madrid

Université catholique de Louvain

University of Alabama, Birmingham

University of Arizona

University of Attiko

University of California, Davis

University of California, Los Angeles

University of California, San Diego

University of California, San Francisco

University of Cincinnati

University of Duesseldorf

University of Erlangen-Nuremberg

University of Franche-Comté

University of Groningen

University of Leipzig

University of London

University of Maryland

University of Miami

University of Michigan

University of Minnesota

University of Montreal

University of Nebraska

University of Nice Sophia Antipolis

University of North Carolina at Chapel Hill

University of Oslo

University of Pittsburgh

University of Sao Paulo

University of South Carolina

University of Southern California

University of South Florida

University of Tennessee

University of Texas at Houston

University of Texas, San Antonio

University of Toronto

University of Turku

University of Virginia

University of Washington

Utrecht University

Vanderbilt University

VentiRx Pharmaceuticals Inc.

Verastem, Inc.

V Foundation

Wake Forest University

Washington University in St. Louis

Wayne State University

Yale University

Yeshiva University

Yonsei University

Zhejiang University

Organization Involved with Phase 1 Indications (70)

Organization Involved with Other Experimental Indications (5)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.